Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system

•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating O...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2021-04, Vol.174, p.108735-108735, Article 108735
Hauptverfasser:	Carlson, Anders L., Huyett, Lauren M., Jantz, Jay, Chang, Albert, Vienneau, Todd, Ly, Trang T.
Format:	Artikel
Sprache:	eng
Schlagworte:	CSII HbA1c Insulin pumps Insulin therapy Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	108735
container_issue
container_start_page	108735
container_title	Diabetes research and clinical practice
container_volume	174
creator	Carlson, Anders L. Huyett, Lauren M. Jantz, Jay Chang, Albert Vienneau, Todd Ly, Trang T.
description	•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating Omnipod. To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems. In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE,
doi_str_mv	10.1016/j.diabres.2021.108735
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2501266554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822721000887</els_id><sourcerecordid>2501266554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-79b2f7c7f92440a1ff0ff61cc657f72bb5c903ffbaeb3c2e2468b49889854a3b3</originalsourceid><addsrcrecordid>eNqFkE1vEzEQhi1ERdOWnwDykQNJ_bFe754QqoBWqsSFni3bOw6O1rvB422Vf49DAldOtkbPzDvzEPKOsw1nvL3dbYZoXQbcCCZ4rXVaqldkxTst1p0Q-jVZVa77878kV4g7xlgrG_WGXEqpOZd9uyIvD2mf52cY6HY8eEjRUz9PJc8jjROVH1UvqB2WsSB9ieUnLYc9UEGP2VAAaYJxjGXBSscSbYnTllpaFgcj4LGKy1gHJTvZLSSYCsUDFkg35CLYEeHt-b0mT1-__Li7Xz9-__Zw9_lx7Rsuylr3TgTtdehF0zDLQ2AhtNz7VumghXPK90yG4Cw46QWIpu1c03dd36nGSievyYfT3HrlrwWwmBTR16XtBPOCRijGRdsq1VRUnVCfZ8QMwexzTDYfDGfm6NzszNm5OTo3J-e17_05YnEJhn9dfyVX4NMJgHroc4Rs0EeYPAwxgy9mmON_In4DHIaWtg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501266554</pqid></control><display><type>article</type><title>Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system</title><source>Access via ScienceDirect (Elsevier)</source><creator>Carlson, Anders L. ; Huyett, Lauren M. ; Jantz, Jay ; Chang, Albert ; Vienneau, Todd ; Ly, Trang T.</creator><creatorcontrib>Carlson, Anders L. ; Huyett, Lauren M. ; Jantz, Jay ; Chang, Albert ; Vienneau, Todd ; Ly, Trang T.</creatorcontrib><description><![CDATA[•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating Omnipod. To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems. In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline HbA1c category. Change (mean ± SD) in HbA1c was −1.3 ± 1.7% [−14 ± 19 mmol/mol] overall, −1.4 ± 1.7% [−15 ± 19 mmol/mol] for prior MDI users, and −0.9 ± 1.5% [−10 ± 16 mmol/mol] for prior CSII users (p<0.0001). The percentage of patients with HbA1c ≥9% [≥75 mmol/mol] decreased (49% to 19%), and with HbA1c <7% [<53 mmol/mol] increased (10% to 22%) (p<0.0001). Prior therapy, age, and baseline HbA1c category were factors affecting change in HbA1c (p<0.05). Reductions in TDD (overall, −33 ± 52U, p<0.0001) and HE per week (overall, −0.5 ± 2.0, p<0.0001), were seen regardless of prior treatment, age, or baseline HbA1c. Omnipod System use was associated with statistically and clinically meaningful reductions in HbA1c, TDD, and HE compared to prior treatments in T2DM.]]></description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2021.108735</identifier><identifier>PMID: 33711396</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>CSII ; HbA1c ; Insulin pumps ; Insulin therapy ; Type 2 diabetes</subject><ispartof>Diabetes research and clinical practice, 2021-04, Vol.174, p.108735-108735, Article 108735</ispartof><rights>2021 Insulet Corporation</rights><rights>Copyright © 2021 Insulet Corporation. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-79b2f7c7f92440a1ff0ff61cc657f72bb5c903ffbaeb3c2e2468b49889854a3b3</citedby><cites>FETCH-LOGICAL-c412t-79b2f7c7f92440a1ff0ff61cc657f72bb5c903ffbaeb3c2e2468b49889854a3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diabres.2021.108735$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33711396$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carlson, Anders L.</creatorcontrib><creatorcontrib>Huyett, Lauren M.</creatorcontrib><creatorcontrib>Jantz, Jay</creatorcontrib><creatorcontrib>Chang, Albert</creatorcontrib><creatorcontrib>Vienneau, Todd</creatorcontrib><creatorcontrib>Ly, Trang T.</creatorcontrib><title>Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description><![CDATA[•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating Omnipod. To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems. In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline HbA1c category. Change (mean ± SD) in HbA1c was −1.3 ± 1.7% [−14 ± 19 mmol/mol] overall, −1.4 ± 1.7% [−15 ± 19 mmol/mol] for prior MDI users, and −0.9 ± 1.5% [−10 ± 16 mmol/mol] for prior CSII users (p<0.0001). The percentage of patients with HbA1c ≥9% [≥75 mmol/mol] decreased (49% to 19%), and with HbA1c <7% [<53 mmol/mol] increased (10% to 22%) (p<0.0001). Prior therapy, age, and baseline HbA1c category were factors affecting change in HbA1c (p<0.05). Reductions in TDD (overall, −33 ± 52U, p<0.0001) and HE per week (overall, −0.5 ± 2.0, p<0.0001), were seen regardless of prior treatment, age, or baseline HbA1c. Omnipod System use was associated with statistically and clinically meaningful reductions in HbA1c, TDD, and HE compared to prior treatments in T2DM.]]></description><subject>CSII</subject><subject>HbA1c</subject><subject>Insulin pumps</subject><subject>Insulin therapy</subject><subject>Type 2 diabetes</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1vEzEQhi1ERdOWnwDykQNJ_bFe754QqoBWqsSFni3bOw6O1rvB422Vf49DAldOtkbPzDvzEPKOsw1nvL3dbYZoXQbcCCZ4rXVaqldkxTst1p0Q-jVZVa77878kV4g7xlgrG_WGXEqpOZd9uyIvD2mf52cY6HY8eEjRUz9PJc8jjROVH1UvqB2WsSB9ieUnLYc9UEGP2VAAaYJxjGXBSscSbYnTllpaFgcj4LGKy1gHJTvZLSSYCsUDFkg35CLYEeHt-b0mT1-__Li7Xz9-__Zw9_lx7Rsuylr3TgTtdehF0zDLQ2AhtNz7VumghXPK90yG4Cw46QWIpu1c03dd36nGSievyYfT3HrlrwWwmBTR16XtBPOCRijGRdsq1VRUnVCfZ8QMwexzTDYfDGfm6NzszNm5OTo3J-e17_05YnEJhn9dfyVX4NMJgHroc4Rs0EeYPAwxgy9mmON_In4DHIaWtg</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Carlson, Anders L.</creator><creator>Huyett, Lauren M.</creator><creator>Jantz, Jay</creator><creator>Chang, Albert</creator><creator>Vienneau, Todd</creator><creator>Ly, Trang T.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system</title><author>Carlson, Anders L. ; Huyett, Lauren M. ; Jantz, Jay ; Chang, Albert ; Vienneau, Todd ; Ly, Trang T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-79b2f7c7f92440a1ff0ff61cc657f72bb5c903ffbaeb3c2e2468b49889854a3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>CSII</topic><topic>HbA1c</topic><topic>Insulin pumps</topic><topic>Insulin therapy</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carlson, Anders L.</creatorcontrib><creatorcontrib>Huyett, Lauren M.</creatorcontrib><creatorcontrib>Jantz, Jay</creatorcontrib><creatorcontrib>Chang, Albert</creatorcontrib><creatorcontrib>Vienneau, Todd</creatorcontrib><creatorcontrib>Ly, Trang T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carlson, Anders L.</au><au>Huyett, Lauren M.</au><au>Jantz, Jay</au><au>Chang, Albert</au><au>Vienneau, Todd</au><au>Ly, Trang T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2021-04</date><risdate>2021</risdate><volume>174</volume><spage>108735</spage><epage>108735</epage><pages>108735-108735</pages><artnum>108735</artnum><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract><![CDATA[•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating Omnipod. To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems. In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline HbA1c category. Change (mean ± SD) in HbA1c was −1.3 ± 1.7% [−14 ± 19 mmol/mol] overall, −1.4 ± 1.7% [−15 ± 19 mmol/mol] for prior MDI users, and −0.9 ± 1.5% [−10 ± 16 mmol/mol] for prior CSII users (p<0.0001). The percentage of patients with HbA1c ≥9% [≥75 mmol/mol] decreased (49% to 19%), and with HbA1c <7% [<53 mmol/mol] increased (10% to 22%) (p<0.0001). Prior therapy, age, and baseline HbA1c category were factors affecting change in HbA1c (p<0.05). Reductions in TDD (overall, −33 ± 52U, p<0.0001) and HE per week (overall, −0.5 ± 2.0, p<0.0001), were seen regardless of prior treatment, age, or baseline HbA1c. Omnipod System use was associated with statistically and clinically meaningful reductions in HbA1c, TDD, and HE compared to prior treatments in T2DM.]]></abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>33711396</pmid><doi>10.1016/j.diabres.2021.108735</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0168-8227
ispartof	Diabetes research and clinical practice, 2021-04, Vol.174, p.108735-108735, Article 108735
issn	0168-8227 1872-8227
language	eng
recordid	cdi_proquest_miscellaneous_2501266554
source	Access via ScienceDirect (Elsevier)
subjects	CSII HbA1c Insulin pumps Insulin therapy Type 2 diabetes
title	Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20glycemic%20control%20in%203,592%20adults%20with%20type%202%20diabetes%20mellitus%20initiating%20a%20tubeless%20insulin%20management%20system&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Carlson,%20Anders%20L.&rft.date=2021-04&rft.volume=174&rft.spage=108735&rft.epage=108735&rft.pages=108735-108735&rft.artnum=108735&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2021.108735&rft_dat=%3Cproquest_cross%3E2501266554%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501266554&rft_id=info:pmid/33711396&rft_els_id=S0168822721000887&rfr_iscdi=true